Naloxone Accord (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naloxone Accord, is an opioid antagonist presented as an injectable solution for intravenous use. It rapidly reverses the effects of opioid overdose in emergency situations. GNH USA supplies Naloxone Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naloxone is an opioid antagonist used in the management of opioid overdose and related emergencies. - Opioid overdose: rapid reversal of respiratory depression, sedation and pinpoint pupils caused by opioid agonists. - Opioid‑induced respiratory depression: restores adequate breathing and oxygenation. - Opioid toxicity: counteracts central nervous system depression and improves consciousness.

Naloxone may cause a range of adverse reactions after administration.

Common Side Effects: - Nausea - Vomiting - Sweating - Tachycardia - Hypertension - Headache - Dizziness

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Cardiac arrhythmias - Pulmonary edema - Seizures - Anaphylactic or severe allergic reactions - Acute opioid withdrawal syndrome

Naloxone should be used with careful clinical assessment and monitoring. - Assess patient: confirm opioid overdose before administration. - Monitor vital signs: observe respiratory and cardiovascular status after dosing. - Avoid in patients with known hypersensitivity to naloxone. - Use with caution in individuals with cardiovascular disease. - Store at ambient temperature: keep in the original pack, protect from light and moisture.

Naloxone may interact with other medications that affect the central nervous system or cardiovascular function.

Major Interactions (Avoid): - Opioid agonists (e.g., morphine, fentanyl): can precipitate severe acute withdrawal. - Mixed agonist‑antagonist opioids (e.g., buprenorphine): may reduce naloxone efficacy.

Moderate Interactions (Monitor Closely): - Sedatives such as benzodiazepines: additive CNS depression may persist after naloxone. - Alcohol: may enhance residual respiratory depression. - Tricyclic antidepressants: may increase risk of cardiac effects when combined with naloxone‑induced tachycardia.